MeCP2 duplication causes hyperandrogenism by upregulating LHCGR and downregulating RORα.

Area of Science:

• Endocrinology
• Genetics
• Molecular Biology

Background:

• MECP2 duplication syndrome (MDS) is a severe neurodevelopmental disorder.
• MDS patients exhibit precocious puberty and hyperandrogenism, suggesting a link between MECP2 and male sex hormone regulation.

Purpose of the Study:

• To investigate the role of MECP2 in androgen synthesis and regulation in the testis.
• To elucidate the molecular mechanisms by which MECP2 duplication affects androgen levels.

Main Methods:

• Utilized a mouse model of MECP2 duplication syndrome.
• Investigated MECP2 expression in testicular Leydig cells.
• Analyzed androgen levels, luteinizing hormone receptor (LHCGR) expression, and aromatase activity.
• Examined MeCP2 binding to Lhcgr and Rorα promoter regions.

Main Results:

• MECP2 duplication significantly elevated androgen levels in the mouse model.
• MeCP2 is highly expressed in testicular Leydig cells, the site of androgen synthesis.
• MECP2 duplication upregulated LHCGR and downregulated aromatase expression in the testis.
• Demonstrated MeCP2 binding to the Lhcgr promoter and Rorα CpG island, influencing gene expression.

Conclusions:

• MECP2 plays a critical role in regulating androgen synthesis and metabolism.
• MECP2's function extends beyond the central nervous system to influence sex hormone production.
• These findings highlight a novel non-CNS role for MECP2 in endocrine regulation.